Article Details
Retrieved on: 2018-01-08 02:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>(MENAFN Editorial) ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat patients with cancer and neurodegenerative diseases, announces it has ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here